Evidence map›Paper›PMID 27927064›Full record

Trial reportPharmaceutical biology2017

Clinical efficacy of Yingliu mixture combined with metimazole for treating diffuse goitre with hyperthyroidism and its impact on related cytokines.

Hua Yang, Yilei Cong, Tengfei Wu, Hong Tang, Muhao Ma, Juanhua Zeng, Wenya Zhang, Zhen Lian, Xinyu Yang

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Pharmaceutical biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Emerging therapeutic role ofChinese herbal medicines · 2022
    Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Hua Yanga Department of Endocrinology , Affiliated Longhua Hospital of Shanghai University of Traditional Chinese Medicine , Shanghai , China.
Yilei Conga Department of Endocrinology , Affiliated Longhua Hospital of Shanghai University of Traditional Chinese Medicine , Shanghai , China.
Tengfei Wua Department of Endocrinology , Affiliated Longhua Hospital of Shanghai University of Traditional Chinese Medicine , Shanghai , China.
Hong Tanga Department of Endocrinology , Affiliated Longhua Hospital of Shanghai University of Traditional Chinese Medicine , Shanghai , China.
Muhao Maa Department of Endocrinology , Affiliated Longhua Hospital of Shanghai University of Traditional Chinese Medicine , Shanghai , China.
Juanhua Zenga Department of Endocrinology , Affiliated Longhua Hospital of Shanghai University of Traditional Chinese Medicine , Shanghai , China.
Wenya Zhanga Department of Endocrinology , Affiliated Longhua Hospital of Shanghai University of Traditional Chinese Medicine , Shanghai , China.
Zhen Liana Department of Endocrinology , Affiliated Longhua Hospital of Shanghai University of Traditional Chinese Medicine , Shanghai , China.
Xinyu Yanga Department of Endocrinology , Affiliated Longhua Hospital of Shanghai University of Traditional Chinese Medicine , Shanghai , China.
Longhua Hospital Shanghai University of Traditional Chinese Medicine · CNShanghai University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextYingliu mixture was developed in 1990s by Affiliated Longhua Hospital of Shanghai University of Traditional Chinese Medicine, for treating diffuse goitre with hyperthyroidism (Graves' disease, GD). Former studies have shown Yingliu mixture combined with methimazole (Y-M) can effectively improve thyroid function and decrease thyrotropin-receptor antibody level. Furthermore, we researched its impact on related cytokines to prove that Y-M improve patients' immunity status.

objectiveTo observe the clinical efficacy of Y-M for treating GD.

methodsA total of 120 GD patients were randomly divided into two groups, the treatment and the control groups (n = 60). The treatment group's patients were treated with Y-M. The control group's patients were treated with methimazole alone. Yingliu mixture was orally administered, 25 mL three times daily. Methimazole was administered at 5-25 mg/day. After 12 weeks of the treatment, the cytokines, antibodies related to thyroid function, and Chinese medical syndromes were evaluated.

resultsAfter the treatment, the free triiodothyronine and thyroxine levels in both groups decreased. The thyroid-stimulating hormone level increased in the treatment group. The thyrotropin-receptor antibody levels and TNF-α levels decreased in both groups. In the control group, IL-6 and IFN-γ levels were lower than that before the treatment. In the treatment group, CD4 CLINICAL SYMPTOMS: the total CMS scores for both groups decreased.

conclusionsThe Y-M combination can improve thyroid function, and decrease autoantibodies, cytokines, and clinical symptoms, so its efficacy may surpass that of methimazole alone.

Indexed as

AdultAntithyroid AgentsAutoantibodiesBiomarkersChinaCytokinesDrugs, Chinese HerbalDrug Therapy, CombinationFemaleGraves DiseaseHumansMaleMethimazoleMiddle AgedRecovery of FunctionThyroid Function TestsAntithyroid AgentsAutoantibodiesBiomarkersCytokinesDrugs, Chinese HerbalMethimazoleThyroid HormonesyingliucytokinesGraves’ diseasetraditional Chinese medicine

Identifiers

PMID27927064
PMCPMC6130729
OpenAlexW2560137695

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.